US not to join global effort to find COVID-19 vaccine

Some nations have worked directly to secure supplies of vaccine, but others are pooling efforts to ensure success against a disease that has no geographical boundaries. That cooperative effort, linked with the World Health Organization, would allow nations to take advantage of a portfolio of potential vaccines to ensure their citizens are quickly covered by whichever ones are deemed effective.

Washington: The Trump administration said Tuesday that it will not work with an international cooperative effort to develop and distribute a COVID-19 vaccine because it does not want to be constrained by multilateral groups like the World Health Organization.

The decision to go it alone, first reported by The Washington Post, follows the White House's decision in early July to pull the United States out of the WHO. Trump claims the WHO needs reform and is heavily influenced by China.

Some nations have worked directly to secure supplies of vaccine, but others are pooling efforts to ensure success against a disease that has no geographical boundaries. More than 150 countries are setting up the COVID-19 Vaccines Global Access Facility, or COVAX.

That cooperative effort, linked with the WHO, would allow nations to take advantage of a portfolio of potential vaccines to ensure their citizens are quickly covered by whichever ones are deemed effective.

The WHO says even governments making deals with individual vaccine makers would benefit from joining COVAX because it would provide backup vaccines in case the ones being made through bilateral deals with manufacturers aren't successful.

The United States will continue to engage our international partners to ensure we defeat this virus, but we will not be constrained by multilateral organizations influenced by the corrupt World Health Organization and China," said White House spokesman Judd Deere.

"This president will spare no expense to ensure that any new vaccine maintains our Food and Drug Administration's gold standard for safety and efficacy, is thoroughly tested and saves lives.

Rep. Ami Bera, D-California, said the administration's decision was shortsighted and will hamper the battle to end the pandemic.

Joining COVAX is a simple measure to guarantee US access to a vaccine no matter who develops it first, tweeted Bera, a medical doctor.

This go-it-alone approach leaves America at risk of not getting a vaccine.

The administration's decision, paired with the US withdrawal from the WHO, means the US is abdicating America's global leadership in fighting pandemics, according to Tom Hart, North America director at The ONE Campaign, an advocacy organization co-founded by Bono of the rock band U2.

"Not only does this move put the lives of millions around the world at risk, it could completely isolate Americans from an effective vaccine against COVID-19, Hart said.

A handful of the dozens of experimental COVID-19 vaccines in human testing have reached the last and biggest hurdle looking for the needed proof that they work.

AstraZeneca announced Monday its vaccine candidate has entered the final testing stage in the US. The Cambridge, England-based company said the study will involve up to 30,000 adults from various racial, ethnic and geographic groups.

Two other vaccine candidates began final testing this summer in tens of thousands of people in the US. One was created by the National Institutes of Health and manufactured by Moderna Inc., and the other developed by Pfizer Inc. and Germany's BioNTech.

(With inputs from AP)